Organisation paid for research Program year 2025 Source: CMS Open Payments

Covenant Research

Neither a doctor nor a teaching hospital

Research payments

$8,049,170

1,420 payments

Through program year 2025, Covenant Research is reported as receiving $8,049,170 in research payments, across 1,420 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$2,826,807	1,321
2024	Research	$2,510,006	8
2023	Research	$2,606,011	5
2021	Research	$106,347	86

Breakdown

Who paid Research payments · program years 2021–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $4,066,465 99 payments
Boehringer Ingelheim International GmbH $3,954,055 1,242 payments
Boehringer Ingelheim RCV GmbH & Co KG $28,651 79 payments

Studies the money was for Research payments · program years 2021–2025

Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) $2,512,185 1,234 payments
Hepatic Impairment Study $1,763,783 4 payments
POCC in NASH $1,534,262 90 payments
BI 456906 in NAFLD $1,364,168 2 payments
Obesity Long term safety in patients with CV risk $559,422 2 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $314,623 87 payments
PoCP study in cirrhosis and portal hypertension $728 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.